Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
Abstract
Renal cell carcinoma accounts for 3% of all adult malignant tumors. Common sites of metastases are lungs, bone, liver, brain and adrenal glands. Metastatic disease to the head and neck ranges from 15% to 30%. The 5-year survival rate after nephrectomy is 60%-75%, but with multiorgan metastases the 5-year survival rate is significantly lower, 0-7%. A case is presented of a female patient diagnosed with renal cell carcinoma metastases to the paranasal sinuses, diagnosed and treated at the Department of ENT and Head and Neck Surgery, Zadar General Hospital, Zadar, Croatia. The tumor was surgically removed. Unfortunately, the patient died one year after the procedure due to multiorgan failure. Although metastases of renal cell carcinoma to the head and neck are very rare, it should be first suspected when investigating a metastatic tumor in this region. Surgical excision offers the best hope for long term survival. In case of unresectable tumor, other treatment options should be considered such as radiotherapy, immunotherapy and chemotherapy.Od svih malignih tumora ljudskog organizma tumor bubrega je zastupljen u oko 3% slučajeva. Česta mjesta metastaziranja su pluća, kosti, jetra, mozak i nadbubrežna žlijezda. Pojava metastaza ovoga karcinoma u području glave i vrata kreće se oko 15%-30%. Postotak petogodišnjeg preživljenja nakon nefrektomije je 60%-75%, dok je istovjetno preživljenje s prisutnim metastazama znatno kraće, 0-7%. U ovom radu prikazuje se bolesnica kojoj je dijagnosticiran karcinom bubrega s metastazom u nosnoj šupljini i paranazalnim sinusima. Dijagnostički postupak i kirurško liječenje obavljeno je u Općoj bolnici Zadar, Odjel otorinolaringologije i kirugije glave i vrata. Tumor je uspješno kirurški odstranjen, ali je bolesnica preminula nakon godinu dana zbog višeorganskih metastaza. Metastaza bubrežnog karcinoma u području glave i vrata je vrlo rijetka. Kirurška ekscizija je metoda izbora, a u slučaju neresektabilnog tumora moguće je primijeniti radioterapiju, imunoterapiju i kemoterapiju
